Abiomed, a provider of medical devices that provide circulatory support to acute heart failure patients, has completed public offering of 2.41 million shares of its common stock at $17.38 per share.
Subscribe to our email newsletter
The net proceeds to Abiomed from the offering were approximately $41.7 million, after deducting the underwriting discount and estimated offering expenses. Morgan Stanley & Co was the sole underwriter for the offering.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.